Follicular lymphoma: Related Videos
Learn about new treatments available for patients with relapsed, indolent non-Hodgkin's lymphoma, as well as potential future treatments.
Keywords: Radioimmunotherapy, non-Hodgkin's lymphoma, relapse, Indolent lymphoma, follicular lymphoma, Bexxar, Zevalin, remission, fludarabine, monoclonal antibody, tumor, toxicity, stem cell transplant, cytokines, rituxan, epratuzumab
Whether relapsed or refractory, tune in to learn about treatments for indolent non-Hodgkin's lymphoma.
Keywords: Radioimmunotherapy, non-Hodgkin's lymphoma, relapse, Indolent lymphoma, follicular lymphoma, Bexxar, Zevalin, remission, fludarabine, CHOP or CVP, monoclonal antibody,tumor, toxicity, long-term side effects
Every year, the Lymphoma Research Foundation hosts a forum for people living with lymphoma and the healthcare professionals that care for them. People attending this weekend gathering exchange latest news about treatment and discuss issues important to people living with lymphoma. See highlights from featured speakers in excerpts from the 2002 Lymphoma Forum.
Keywords: lymphoma, non-Hodgkin's lymphoma, NHL, follicular lymphoma, cancer vaccine, BCL-2 antisense oligonucleotide, rituxan, rituximab, CHOP, B cell lymphoma, radioimmunotherapy, antibody, radiation, CLL, Hodgkin's disease, bone marrow transplantation, Bexxar, Zevalin
Almost a quarter of all non-Hodgkin's lymphoma is classfied as follicular lymphoma. However, there are various options for treatment and choosing the best one may depend on the spcific details of your disease, your lifestyle and other symptoms you want to keep under control.
Keywords: non-hodgkin's lymphoma, follicular lymphoma, monoclonal antibodies, radioimmunotherapies, stem cell transplant
» Next page: Types of Follicular lymphoma
Rate This Website
What do you think about the features of this website?
Take our user survey and have your say:
Website User Survey
Medical Tools & Articles:
Next articles:
Tools & Services:
Medical Articles:
Forums & Message Boards
- Ask or answer a question at the Boards: